Innodem Neurosciences’ ETNA Device Receives the US FDA’s Breakthrough Device Designation for the Treatment of Multiple Sclerosis
Shots:
- The US FDA has granted BDD to eye-tracking neurological assessment (ETNA device) for MS. The device is designed to track MS patients' eye movements to estimate disease severity & help clinicians to track disease progression
- Innodem's patented mobile software technology is embodied in an intuitive application to transform an off-the-shelf electronic tablet into a polyvalent & precise device capturing EMBs & GMBs in minutes, remotely informing clinicians about MS disease & progression to improve patient outcomes
- Innodem is conducting a clinical trial to demonstrate that new digital EMBs and GMBs may correctly and cost-effectively monitor improvements in MS patients' quality of treatment and QoL
Ref: Innodem | Image: Innodem
Click here to read the full press release